Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. - Wikidata - awgldk - TriplyDB

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

http://www.wikidata.org/entity/Q33397071

about

Enzyme replacement and substrate reduction therapy for Gaucher disease Hematopoietic stem cell transplantation for Gaucher disease Imiglucerase in the treatment of Gaucher disease: a history and perspective The potential of plants as a system for the development and production of human biologics Putting the Spotlight Back on Plant Suspension Cultures Plant-based vaccines for animals and humans: recent advances in technology and clinical trials Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy Molecular pharming's foot in the FDA's door: Protalix's trailblazing story Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension.Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.Revised recommendations for the management of Gaucher disease in children.Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.Bacterial proteins and peptides in cancer therapy: today and tomorrow Plant glyco-biotechnology on the way to synthetic biology Gaucher disease and its treatment options.Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in health Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).Reversal of succinylcholine induced apnea with an organophosphate scavenging recombinant butyrylcholinesterase.On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes.Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems.Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers.From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery.Treatment options for lysosomal storage disorders: developing insights.Transgenic rice endosperm as a bioreactor for molecular pharming.Enzymes approved for human therapy: indications, mechanisms and adverse effects.New Directions in Gaucher Disease.Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment.

P2860

Q24187121-96BED0CF-2FDB-4729-BAF5-6999B567CE97 Q24202044-BCCCB632-0348-43A9-B124-398975EB0745 Q24631426-25377F5B-264F-484F-90D0-B952043BAB1A Q26747611-C0B7A9A0-3C05-43D2-B5D0-63DB104D0F56 Q26750974-44928D7B-C04C-4D32-919F-4287B9361C90 Q26775788-06EC1DB1-BDFC-4898-8459-FFAC2BFBBFFF Q28067032-18AF1860-A400-4A82-83F3-800D24BAA899 Q28086959-13EB7C51-F105-4300-9CD2-768D14715735 Q30600509-CB79F58C-7182-45C8-A69E-41ACC2A075E1 Q33401459-C705BB78-5A28-4182-AEF8-777C8BBD4195 Q33402191-1C1F7A92-80CA-4444-B111-BC54E3AFB09F Q33403298-14580828-0483-42FB-812E-7C257E5E7525 Q33600272-4545531F-43FB-48B1-9B20-B0416CCB9782 Q33696617-5E272D5D-F6D6-4324-AB63-64B1F19069DC Q33891532-B806BF5C-84F9-466A-9296-7AC3E2D569E9 Q34075830-135B63FD-9E0F-4F31-A869-2683DC501C75 Q34304795-23C3FC12-87BC-4B7B-B812-93125355FAF0 Q34386658-4AC8E972-1273-4950-BA63-5E4FA4FE0318 Q34497705-8603ECAD-278F-4C64-8EC2-DF923F249A6F Q34553589-E81ACAD4-0D1E-4137-9011-F2F554B78E12 Q34639611-A3511858-3D71-4BAC-B138-A53DC62430B8 Q35002326-5423208F-A9BF-45BD-BDA7-7CE483DBC6A3 Q35198538-00B2B60A-76BD-42E5-A0E8-7F6628740775 Q35656456-45B50CF4-2128-449B-A6EA-EE12227BB85B Q35997277-BF36E31C-5239-4FDF-99C1-258DF50FE234 Q36179265-EBF8C884-D883-404F-BFFE-8A46539A3A1B Q36282478-A67AC58B-B5D2-4BF7-BD40-4BE928D9DA68 Q36725221-BBD227CB-FA3E-437F-9949-7CCAE2A6824A Q37127644-D551B20B-C943-4A60-BA79-57F4AAA732BB Q37167690-69D39D33-A35F-4B0E-ABB7-43A708FD87DA Q37196619-DCF086CB-C5DC-44FC-9E61-FC87FC642684 Q37357290-E0D1A026-3BF1-4755-BD0C-FC8E63484961 Q37375665-9CB33E52-9440-4ECC-9A3B-9272C576B801 Q37620814-5E19ECDD-2560-4BDC-8299-E85456A4BE96 Q37620820-39F8DF38-A179-4C76-BAF8-69D18370A4AD Q38046227-4A00C0F0-1400-44E6-A0E3-B3C095E9027D Q38177654-83F5511D-3FAE-489B-80A6-1CF88ABD1ACE Q38342838-98FC997C-1778-44FA-A687-434F03D6E77F Q38905996-F410CAF5-E2A4-4EED-8FC0-807C9A7C4454 Q38955887-8EA70FF8-78AC-4BF8-8C82-9BBEB0B314E3

P2860

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.

http://www.wikidata.org/entity/Q33397071

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@ast

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@en

type

label

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@ast

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@en

prefLabel

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@ast

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@en

P1433

Q33397071-AD5F363C-F713-4B71-A0BC-5534B8770091

P1476

Q33397071-78C32328-3120-485B-B97E-2F962A831C4F

P2093

Q33397071-26EF039A-880B-4BCD-BFC2-25F866CFD3B3

Q33397071-41BF5A4F-3CA6-4AC0-9A58-C7119A1DE69A

Q33397071-434C8F16-7C93-496E-8B06-F20FB454EED8

Q33397071-499DFC97-DBA3-4D5E-9F08-AC932D1BF6CD

Q33397071-5728F5DF-641A-4EFF-8E09-D363CC3BE5AD

Q33397071-7CAD0AE8-7520-45B3-AC1D-AAD42942D4C3

Q33397071-8ABCF2F9-CE77-46AE-987D-FAB82C9716F2

Q33397071-8CB541C5-A832-40E9-A3A6-CB4E76CB105F

Q33397071-8D8D3F15-8EA0-4F15-8B83-01814348226F

Q33397071-B772F917-8AFA-452B-8507-A7EBF45259C5

P304

Q33397071-19CAD287-FD7A-4C65-9C72-18831F2CC739

P31

Q33397071-A90FF1F3-DF0B-4FC1-8FE3-3D923B470028

P356

Q33397071-39B800FF-CDE8-4B29-A56C-DF71904C4E45

P407

Q33397071-5D52F04D-5340-4300-BF45-EBD48E31B07A

P433

Q33397071-4110EA8B-5048-4C1A-AB33-FD2920D2FCE2

P478

Q33397071-F59300DE-3476-43B8-AC81-A1B05551D60B

P50

Q33397071-A3E6F191-D267-408B-9133-E03817697883

P577

Q33397071-97633732-4B28-4BFC-97F9-7C3B31B40332

P5875

Q33397071-32F4E7A6-ECBA-4907-973E-58EE368B54E1

P698

Q33397071-8697AD10-1D39-483C-9358-85366AEBBD46

P921

Q33397071-07829033-4274-47E0-8C3C-6D1586AC5B3B

P356

BLOOD-2011-07-366955

P1433

P1476

Pivotal trial with plant cell- ...... t therapy for Gaucher disease.

@en

P2093

Ari Zimran

http://www.w3.org/2001/XMLSchema#string

Atul Mehta

http://www.w3.org/2001/XMLSchema#string

David Aviezer

http://www.w3.org/2001/XMLSchema#string

Deborah Elstein

http://www.w3.org/2001/XMLSchema#string

Dominick Amato

http://www.w3.org/2001/XMLSchema#string

Eduardo Terreros Muñoz

http://www.w3.org/2001/XMLSchema#string

Einat Brill-Almon

http://www.w3.org/2001/XMLSchema#string

Fiorina Giona

http://www.w3.org/2001/XMLSchema#string

Francisco Blanco-Favela

http://www.w3.org/2001/XMLSchema#string

Gheona Altarescu

http://www.w3.org/2001/XMLSchema#string

P304

5767-5773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-07-366955

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Sergio Solorio-Meza

P577

2011-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51620139

http://www.w3.org/2001/XMLSchema#string

P698

21900191

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy